Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 96 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept Patient Guide in Testicular Cancer Now Available Also in German MOST POPULAR Newest Gerber Baby is Child of Breast Cancer Survivor June 29, 2021 Καρκίνος οισοφάγου January 22, 2019 Bariatric Surgery May Reduce the Risk of Some Common Cancers December 2, 2022 How Living in Service to Others Helped Me Cope During Cancer March 9, 2023 Load more HOT NEWS No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... Vulnerability in Brain Tumors May Open Door to New Treatments T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... FDA Approves Imetelstat for Low- To Intermediate-1 Risk Myelodysplastic Syndromes with...
